Real-Time Benefit Tool Implementation Act
Latest Action
Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-549, Part I.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Real-Time Benefit Tool Implementation Act (H.R. 7512) is a health policy bill introduced in the 118th Congress aimed at implementing a real-time benefit tool. This tool is intended to provide immediate information about patient-specific prescription drug benefits and costs at the point of prescribing. The bill was considered by the House Committee on Ways and Means and reported with amendments but ultimately failed or expired without becoming law. The bill's text and detailed summary are not available, limiting the ability to provide a comprehensive analysis of its provisions.
H.R. 7512 sought to enhance transparency and efficiency in prescription drug benefit information through a real-time tool but did not advance to enactment during the 118th Congress.
- The bill focuses on implementing a real-time benefit tool related to prescription drug coverage.
- It was reported (amended) by the House Committee on Ways and Means, indicating some legislative consideration.
- The bill did not pass and is currently classified as failed or expired.
['Patients seeking prescription drugs who would receive real-time cost and benefit information.', 'Healthcare providers who would have access to immediate benefit data to inform prescribing decisions.', 'Health insurance plans and pharmacy benefit managers potentially involved in providing data for the tool.']
['Lack of publicly available full bill text limits assessment of implementation details and cost implications.', 'Potential challenges in integrating real-time data systems across multiple insurers and providers.', 'Oversight and enforcement mechanisms for ensuring accuracy and privacy of benefit information are unclear.']
The bill was introduced and considered during the 118th Congress, with activity recorded up to June 2024. It was reported out of the House Committee on Ways and Means with amendments but did not advance further, resulting in its failure or expiration. The policy area is health, specifically focusing on prescription drug benefits transparency.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Improved prescribing efficiency and patient cost awareness could reduce prescription abandonment or non-adherence.', 'Potential increased administrative burden on providers and insurers to maintain real-time data accuracy.', 'Possible influence on drug pricing negotiations due to increased transparency.']
The lack of a publicly available full bill text and official summary limits transparency and comprehensive analysis. Future legislative efforts should ensure accessible documentation to facilitate public understanding and oversight. Monitoring the technical feasibility and privacy safeguards of real-time benefit tools is essential for effective implementation.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.